References
- Andersen PM, Nilsson P, Keranen ML, Forsgren L, Hagglund J, Karlsborg M, et al. Phenotypic heterogeneity in motor neuron disease patients with Cu/Zn superoxide dismutase mutations in Scandinavia. Brain. 1997; 120: 1723–37
- Cudkowicz ME, McKenna-Yasek D, Sapp PE, Chin W, Geller B, Hayden DL, et al. Epidemiology of mutations in superoxide dismutase in amyotrophic lateral sclerosis. Ann Neurol. 1997; 41: 210–21
- Gamez J, Corbera-Bellalta M, Nogales G, Raguer N, Garcia-Arumi E, Badia-Canto M, et al. Mutational analysis of the Cu/Zn superoxide dismutase gene in a Catalan ALS population: should all sporadic ALS cases also be screened for SOD1?. J Neurol Sci. 2006; 247: 21–8
- Jones CT, Swingler RJ, Simpson SA, Brock DJ. Superoxide dismutase mutations in an unselected cohort of Scottish amyotrophic lateral sclerosis patients. J Med Genet. 1995; 32: 290–2
- Hosler BA, Nicholson GA, Sapp PC, Chin W, Orrell RW, de Belleroche JS, et al. Three novel mutations and two variants in the gene for Cu/Zn superoxide dismutase in familial amyotrophic lateral sclerosis. Neuromuscul Disord. 1996; 6: 361–6
- Ilzecka J, Stelmasiak Z. Creatine kinase activity in amyotrophic lateral sclerosis patients. Neurol Sci. 2003; 24: 286–7
- Lee JH, Shin JH, Park KP, Kim IJ, Kim CM, Lim JG, et al. Phenotypic variability in Kennedy's disease: implication of the early diagnostic features. Acta Neurol Scand. 2005; 112: 57–63
- Rudnik-Schoneborn S, Lutzenrath S, Borkowska J, Karwanska A, Hausmanowa-Petrusewicz I, Zerres K. Analysis of creatine kinase activity in 504 patients with proximal spinal muscular atrophy types I–III from the point of view of progression and severity. Eur Neurol. 1998; 39: 154–62
- Waring WP, Davidoff G, Werner R. Serum creatine kinase in the post-polio population. Am J Phys Med Rehabil. 1989; 68: 86–90
- Drachman DB, Murphy SR, Nigam MP, Hills JR. ‘Myopathic’ changes in chronically denervated muscle. Arch Neurol. 1967; 16: 14–24